NCT07552077Phase 2Recruiting

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Study sponsor: Palvella Therapeutics, Inc. · PVLA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-08Estimated
Enrollment · participants15Estimated
Source updated2026-04-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.